Clinical and Radiological Evaluation of Hypopharyngeal Carcinoma.

Clinical and Radiological Evaluation of Hypopharyngeal Carcinoma. Adv Otorhinolaryngol. 2019;83:35-46 Authors: Piazza C, Paderno A, Ravanelli M, Pessina C Abstract Pre-treatment clinical and radiological evaluations represent a key step in the proper management of hypopharyngeal carcinoma. First, office-based endoscopy allows the assessment of superficial tumor extension, signs of laryngeal infiltration, and the overall residual function of the laryngo-hypopharyngeal complex. Different tools, maneuvers, and techniques can improve this essential diagnostic step and should be considered a prerequisite to direct subsequent investigations and give an initial indication for the most appropriate treatment. Furthermore, radiologic investigations help in determining tumor deep infiltration, lymph nodes involvement, and the presence of distant metastases. These should complement clinical evaluation by giving a more precise view of the disease characteristics, its overall behavior, and pattern of spreading. The aim of the current review is to summarize the key points that should be considered when approaching hypopharyngeal tumors from a diagnostic perspective, by presenting the main advantages and drawbacks of each technique. PMID: 30943514 [PubMed - in process]
Source: Advances in Oto-Rhino-Laryngology - Category: ENT & OMF Tags: Adv Otorhinolaryngol Source Type: research

Related Links:

Abstract Head and neck cancers are among the 10 most common cancers in the world and include cancers of the oral cavity, hypopharynx, larynx, nasopharynx, and oropharynx. At least 90% of head and neck cancers are squamous cell carcinomas (SCCs). This summary discusses the integration of clinical and mechanistic studies in achieving diagnostic and therapeutic precision in the context of oral cancer. Specifically, based on recent mechanistic studies, a subsequent study reevaluated current diagnostic criteria of perineural invasion in patients with oral cavity SCC showing that overall survival could be associated wit...
Source: Adv Dent Res - Category: Dentistry Authors: Tags: Adv Dent Res Source Type: research
AbstractIn patients with locally advanced human papillomavirus (HPV)-unrelated head and neck squamous-cell carcinoma (HNSCC), cisplatin and radiation therapy (CisRT) resulted in a local –regional recurrence (LRR) rate of 35%, progression-free survival (PFS) of 49%, and overall survival (OS) of 60%. We, and others, showed thatnab-paclitaxel is an active agent in metastatic and locally advanced HNSCC. The aim of this report was to assess the efficacy ofnab-paclitaxel-based induction chemotherapy and CisRT in HPV-unrelated HNSCC. We performed a retrospective single-institution analysis of patients treated withnab-paclit...
Source: Medical Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsA single-cycle induction chemotherapy for HNSCC enables surgery plus adjuvant therapy as well as chemoradiotherapy. The long-term local and distant disease control was good but varied between tumors in the larynx and mesopharynx/tongue vs. hypopharynx.
Source: European Archives of Oto-Rhino-Laryngology - Category: ENT & OMF Source Type: research
This retrospective study evaluated operative outcomes when using a supraclavicular artery island flap (SAIF) combined with a sternohyoid muscle flap (SHMF) to reconstruct defects after hypopharyngeal carcinoma resection. Reconstructive surgery for hypopharyngeal and laryngeal defects was performed with the SAIF + SHME combination in 6 patients during 2016 to 2018. Within 14 to 16 days after the surgery, all 6 patients could ingest food and block the tube (avoiding aspiration), with no pharyngeal fistulas. They then underwent irradiation up to a total of 60.5 Gy during the 4 weeks postoperatively. All 6 flaps survived, and ...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Observational Study Source Type: research
ConclusionsThe impact of irAEs on outcomes could be mistaken if not taking into consideration the ICI duration because the likelihood of irAEs and OR increases with treatment duration. Using a Landmark analysis with 90 d cut-off, we did not observe an association between irAEs and outcome in R/M HNSCC.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureN. Baste Rotllan: Advisory / Consultancy, Travel / Accommodation / Expenses: Merck Serono; Advisory / Consultancy: MSD; Advisory / Consultancy, Travel / Accommodation / Expenses: Bristol Meyers Squibb; Advisory / Consultancy, Trave...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsFU-FDG-PET/CT in real-life has a high NPV and significant prognostic value. However, false-positive scans induce invasive procedures in a significant fraction of patients.Legal entity responsible for the studyThe authors.FundingHas not received any funding.DisclosureAll authors have declared no conflicts of interest.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsThe recommended phase 2 dose was palbociclib 125  mg/d for 21 days on and 7 days off with full standard dose of cetuximab and IMRT for locally advanced SCCHN. MTD was not achieved. The combination was well tolerated with promising preliminary efficacy. The expansion cohort of palbociclib 125 mg/d is currently accruing up to 15 locally advanced p16-negative SCCHN patients.Clinical trial identificationNCT#03024489.Legal entity responsible for the studyThe authors.FundingPfizer.DisclosureN. Ngamphaiboon: Honoraria (self), Advisory / Consultancy, Speaker Bureau / Expert testimony, Research grant / Fund...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsIn this phase IIIb trial, nivolumab confirmed the safety and efficacy profile of the registration trial. Experiencing any grade TR AE revealed to be a favorable prognostic factor, as possible expression of effective immune response.Legal entity responsible for the studyGONO group.FundingBristol Myers-Squibb.DisclosureP. Bossi: Advisory / Consultancy: AstraZeneca; Advisory / Consultancy: BMS; Advisory / Consultancy: Angelini; Advisory / Consultancy: MSD; Advisory / Consultancy: Merck Serono; Advisory / Consultancy: Voluntis. M.C. Merlano: Honoraria (self), consultancy or A.B.: Bristol M.S.; Honoraria (self), cons...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
ConclusionsThe substudy of mona in monotherapy did not meet its primary objective and was closed at interim for futility. Median PFS was 7.4 wks. Mona has a favorable safety profile and is under investigation in combination with durvalumab within the UPSTREAM trial.Clinical trial identificationNCT03088059.Legal entity responsible for the studyEORTC.FundingEORTC, Innate Pharma.DisclosureR. Galot: Advisory / Consultancy: Innate Pharma; Travel / Accommodation / Expenses: Amgen; Travel / Accommodation / Expenses: Astellas. C. Le Tourneau: Advisory / Consultancy: MSD; Advisory / Consultancy: Merck-Serono; Advisory / Consultancy...
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
Conclusions: HART represents an attractive approach for patients with HNSCC where treatment intensification is indicated. PMID: 31519130 [PubMed - as supplied by publisher]
Source: Acta Oncologica - Category: Cancer & Oncology Authors: Tags: Acta Oncol Source Type: research
More News: Cancer & Oncology | Carcinoma | Endoscopy | ENT & OMF | Hypopharyngeal Cancer | Laryngeal Cancer